🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,187

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

875 results for “A.” Clear

  1. Placebo, Obicetrapib 10 mg + ezetimibe 10 mg fixed dose combination (FDC)

    Pharma Mar S.A.

    Atherosclerotic Cardiovascular Disease

    phase 3 small molecule active

    1 trial

  2. Placebo, Paltusotine 40 mg tablets, Paltusotine 40 mg tablets

    Pharma Mar S.A.

    Carcinoid syndrome

    phase 3 small molecule active

    1 trial

  3. Placebo, capsule, ZYTIGA 500 mg film-coated tablets, Prednison acis 5 mg, Tabletten, Fuzuloparib

    Pharma Mar S.A.

    Metastatic Castration-Resistant Prostate Cancer

    phase 3 small molecule active

    1 trial

  4. Placebo, oral solution, Maralixibat chloride

    Pharma Mar S.A.

    Cholestatic Pruritus

    phase 3 small molecule active

    1 trial

  5. PolyCore

    Pharma Mar S.A.

    Congestive Heart Failure

    phase 3 small molecule active

    1 trial

  6. Powder for reconstitution for enteral administration

    Pharma Mar S.A.

    Intestinal Malabsorption

    phase 3 small molecule active

    1 trial

  7. Powder for reconstitution for enteral administration

    Pharma Mar S.A.

    Intestinal Malabsorption

    phase 3 small molecule active

    1 trial

  8. Pozelimab, Cemdisiran

    Pharma Mar S.A.

    Paroxysmal nocturnal hemoglobinuria (PNH)

    phase 3 small molecule active

    1 trial

  9. Prednisolon STADA® 5 mg Tabletten, Prednisolone placebo hard capsule and tablet, Normal Saline, Prednisolon STADA® 10 mg Tabletten, [1-13C]SODIUM ACETATE, Avalotcagene ontaparvovec

    Pharma Mar S.A.

    Late-onset Ornithine transcarbamylase (OTC) deficiency

    phase 3 small molecule active

    1 trial

  10. Prednisolon STADA® 5 mg Tabletten, Prednisolone placebo hard capsule, 10 mg, Prednisolone Placebo hard capsule, 5mg, Prednisolon STADA® 10 mg Tabletten, Pariglasgene brecaparvovec, Normal Saline

    Pharma Mar S.A.

    Glycogen Storage Disease Type Ia (GSDIa)

    phase 3 small molecule active

    1 trial

  11. Priorix - Pulver und Lösungsmittel zur Herstellung einer Injektionslösung in einer Fertigspritze|Masern-Mumps-Röteln-Lebendimpfstoff, Priorix - Pulver und Lösungsmittel zur Herstellung einer Injektionslösung in einer Fertigspritze|Masern-Mumps-Röteln-Lebendimpfstoff, VARIVAX® Pulver und Lösungsmittel zur Herstellung einer Injektionssuspension in einer Fertigspritze Varizellen-Lebendimpfstoff, Priorix - Pulver und Lösungsmittel zur Herstellung einer Injektionslösung in einer Fertigspritze|Masern-Mumps-Röteln

    GlaxoSmithKline Biologicals S.A.

    Varicella

    phase 3 small molecule active

    1 trial

  12. ProAir® Digihaler®, Placebo TEV-56248, Albuterol Sulfate HFA, ArmonAir® Digihaler®, Fluticasone propionate,Salbutamol sulfate

    Pharma Mar S.A.

    Asthma

    phase 3 small molecule active

    1 trial

  13. Prolastin 1000 mg, Pulver und Lösungsmittel zur Her- stellung einer Infusionslösung, Prolastin 5000 mg, Pulver und Lösungsmittel zur Herstellung einer Infusionslösung, Prolastin 4000 mg, Pulver und Lösungsmittel zur Herstellung einer Infusionslösung

    Instituto Grifols S.A.

    Severe Alpha-1 Antitrypsin Deficiency (AATD)

    phase 3 small molecule active

    1 trial

  14. QL2107, PEMBROLIZUMAB

    Pharma Mar S.A.

    Non-small cell lung cancer

    phase 3 small molecule active

    1 trial

  15. Qutenza 179 mg cutaneous patch, CAPSAICIN, Qutenza 179 mg cutaneous patch

    Pharma Mar S.A.

    Post-surgical neuropathic pain

    phase 3 small molecule active

    1 trial

  16. RANOLAZINE, FLECARDIA Διάλυμα για ένεση/έχχυση

    Pharma Mar S.A.

    Restoration of sinus rhythm in patients with recent AF onset

    phase 3 small molecule active

    1 trial

  17. REGN4461 - Mibavademab

    Pharma Mar S.A.

    Monogenic obesity

    phase 3 small molecule active

    1 trial

  18. REGN7508, CLEXANE 4 000 UI (40 mg)/0,4 ml solution injectable en seringue préremplie, Eliquis 2.5 mg film-coated tablets, SODIUM CHLORIDE, REGN7508

    Pharma Mar S.A.

    Thromboembolic disease

    phase 3 small molecule active

    1 trial

  19. RITUXIMAB, Capsule, hard, Calquence 100 mg hard capsules, BENDAMUSTINE

    Pharma Mar S.A.

    Mantle Cell Lymphoma

    phase 3 small molecule active

    1 trial

  20. Rilzabrutinib, Composition of placebo is identical to that of IMP except that 400mg active ingredient is replaced with 400mg mannitol.

    Pharma Mar S.A.

    Immune Thrombocytopenia (ITP)

    phase 3 small molecule active

    1 trial

  21. Rozanolixizumab, also known as UCB7665, Rystiggo 140 mg/ml solution for injection, -

    Pharma Mar S.A.

    Myelin oligodendrocyte glycoprotein antibody-associated disease (MOG-AD)

    phase 3 small molecule active

    1 trial

  22. Soliris 300 mg concentrate for solution for infusion, Pozelimab, Cemdisiran, Ultomiris 300 mg/3 mL concentrate for solution for infusion

    Pharma Mar S.A.

    Paroxysmal nocturnal haemoglobinuria (PNH)

    phase 3 small molecule active

    1 trial

  23. Solution for Injection, subcutaneous Use, IMCIVREE 10 mg/ml solution for injection

    Pharma Mar S.A.

    Improper function of certain messenger materials in the body that control body weight and hunger in people

    phase 3 small molecule active

    1 trial

  24. Sovateltide, Sovateltide matching placebo

    Pharma Mar S.A.

    Acute cerebral ischemic stroke

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources